Bill Sellers, head of Broad’s Cancer Program, talks about how to discover new classes of genetic dependencies that could move therapies closer to curing cancer patients.
Efforts to probe the entire genome of cancer cells in animals have led to potential new drugs — now in early-stage clinical trials — that could make cancer immunotherapy more effective for more patients.
A study of tumor exomes reconstructs a timeline of mutations for certain cancer types, revealing insight into the order of genetic drivers of the disease.
By integrating clinical, genetic, and other data from patients with lung cancer, researchers identify biological factors that could help predict treatment outcomes.
The new Leiomyosarcoma Project joins an existing effort, Count Me In’s Osteosarcoma Project, to partner with patients and accelerate scientific discovery in rare cancers.